Navigation Links
Data supporting three Antisoma programmes presented at AACR

The Trout Group +1 646 378 2923

Except for the historical information presented, certain matters discussed in this statement are forward looking statements that are subject to a number of risks and uncertainties that could cause actual results to differ materially from results, performance or achievements expressed or implied by such statements. These risks and uncertainties may be associated with product discovery and development, including statements regarding the company's clinical development programmes, the expected timing of clinical trials and regulatory filings. Such statements are based on management's current expectations, but actual results may differ materially.

Notes for Editors:

AS1404 AS1404 (DMXAA) is a small-molecule vascular disrupting agent which targets the blood vessels that nourish tumours. The drug was discovered by Professors Bruce Baguley and William Denny and their teams at the Auckland Cancer Society Research Centre, University of Auckland, New Zealand. It was in-licensed by Antisoma from Cancer Research Ventures Limited (now Cancer Research Technology), the development and commercialisation company of the Cancer Research Campaign (now Cancer Research UK), in August 2001. CRUK had supported two phase I studies in the UK and New Zealand. AS1404 has shown a substantial survival benefit in patients with non-small cell lung cancer when added to paclitaxel-based chemotherapy in a randomised phase II study. Initial response findings from other phase II studies in ovarian and prostate cancers have also been positive.

AS1411 Aptamers are short pieces of DNA or RNA that can fold into stable, three-dimensional structures capable of interacting with particular target proteins. AS1411 is the first aptamer to be tested as a treatment for cancer. It binds to the protein nucleolin, which is found on the surface of cancer cells. It is then internalised and
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Antisoma plc (UK) - Second lung cancer trial adds to positive data on AS1404
3. CYT003-QbG10 to treat allergy to be presented at the Congress of the European Academy of Allergology and Clinical Immunology (EAACI), June 9-13, 2007
4. Data to be presented at AAN Meeting -Study results of drug candidate for MS
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Data supporting three Antisoma programmes presented AACR
(Date:11/26/2014)...  Medtronic,s roughly $43 billion acquisition and ... in the media for its US Federal tax ... player in one of the fastest growing device ... research firm said  the two companies compete in ... of solutions spanning inpatient to home care, and ...
(Date:11/26/2014)... -- Unilife Corporation (NASDAQ: UNIS, ASX: UNS), a designer, manufacturer ... that its Chairman and CEO, Alan Shortall , ... Annual Healthcare Conference at the New York Palace Hotel ... The conference presentation will be broadcast ... To listen, please go to: http://ir.unilife.com/events.cfm . An ...
(Date:11/26/2014)... OAKS, Calif. and LONDON , ... ) and AstraZeneca (NYSE: AZN ) today announced ... evaluating two doses of brodalumab in more than 1,800 patients ... with both Stelara ® (ustekinumab) and placebo at week ... brodalumab weight-based analysis group were each shown to be superior ...
Breaking Medicine Technology:Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
(Date:11/26/2014)... Sonoran Vein and Endovascular nurse, ... Distinguished Preceptorship Award from The American Association ... the advancement of nurse practitioners. The Distinguished Preceptorship ... had made a significant contribution toward increasing the ... of Nurse Practitioners (AANP) is the largest full-service ...
(Date:11/26/2014)... Nov. 25, 2014 (HealthDay News) -- Youngsters who enter ... new study suggests. Early puberty was linked with ... poor self-image and high anxiety levels, according to the ... such as conflict with family and peers, and having ... study found. Although the study found an association ...
(Date:11/26/2014)... TUESDAY, Nov. 25, 2014 (HealthDay News) -- Teens ... likely to abuse those drugs than other teens, ... the need to conduct substance abuse assessments on ... researchers said. "Prescribers and parents don,t realize ... a professor at the University of Michigan School ...
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- Exposure to peanut protein ... allergy in infants with the skin condition eczema, a ... children in the United States are allergic to peanuts. ... food allergies, particularly peanut allergy, the researchers noted. ... to 15 months. The researchers examined the amount of ...
(Date:11/26/2014)... Randy Dotinga HealthDay Reporter ... drugs such as Prilosec and Nexium may disrupt the makeup ... of infections and other problems, a small new study suggests. ... it more likely users will become ill, and study authors ... inhibitors. However, these antacids "should be used at the ...
Breaking Medicine News(10 mins):Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2Health News:Infants With Eczema May Be More Prone to Peanut Allergy: Study 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 3
... patients with the blood cancer , , WEDNESDAY, July 9 ... once-banned drug thalidomide for patients with myeloma have learned ... is to science: Don,t judge results too early. , ... increased the odds of a complete remission, but not ...
... Weight Watchers,International, Inc. (NYSE: WTW ) will release ... close on Thursday, July 31, 2008., The Company ... at 5:00,p.m. ET. During the conference call, David Kirchhoff, ... Officer, will discuss,second quarter results and answer questions from ...
... its,efforts to ensure the State,s leaders are putting patients ... for Patient Care (CPC), a,non-profit, patient-advocacy organization, hand delivered ... as other key leaders in the,State Legislature today., ... with a better,understanding of how devastating these massive health ...
... be done without destroying embryo , , WEDNESDAY, July 9 ... in developing human embryonic stem cells earlier in the ... embryo, so the whole embryo is not destroyed. , ... European Society of Human Reproduction & Embryology annual conference ...
... Pain Centers (SCPC) have been shown to perform better ... for Medicare and Medicaid Services (CMS) as compared to ... an Emory University researcher. , The findings, ... for observation medicine in the Emory University School of ...
... Holdings, Inc.,(NYSE and SWX: ZMH) announced today its second ... live over the Internet on,Thursday, July 24, 2008, at ... results will be made available at 7:00 a.m. the,morning ... can be accessed via Zimmer,s Investor Relations,website at ...
Cached Medicine News:Health News:Thalidomide Continues to Show Benefits Against Myeloma 2Health News:Thalidomide Continues to Show Benefits Against Myeloma 3Health News:Weight Watchers Announces Second Quarter 2008 Earnings Conference Call 2Health News:CPC Hand-Delivers Patient Testimonies to State Leaders Pleading for No Budget Cuts to Health and Human Services 2Health News:New Technique Harvests Stem Cells at Earlier Stage 2Health News:New Technique Harvests Stem Cells at Earlier Stage 3Health News:Chest pain center accreditation linked with better outcomes in heart attack patients 2
Intermittent catheter...
Intermittent catheter...
Intermittent catheter...
... proBNP assay is a rapid and accurate bedside ... system assisting the diagnosis and assessment of patients ... both speed and accuracy profit from ... proBNP assay = 12 minutes. In emergency departments ...
Medicine Products: